ellingson bm et al ., neuro oncol. 2012 14(4):333-43

18
lingson BM et al., Neuro Oncol. 2012 14(4):333-43.

Upload: glenna-hunt

Post on 02-Jan-2016

24 views

Category:

Documents


0 download

DESCRIPTION

Ellingson BM et al ., Neuro Oncol. 2012 14(4):333-43. Ellingson BM et al ., Neuro Oncol. 2012 14(4):333-43. Ellingson BM et al., Neuro Oncol. 2011 13(10):1151-61. Instead of quantifying the absolute difference in ADC, CIMPLE - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Ellingson BM  et al ., Neuro Oncol. 2012 14(4):333-43

Ellingson BM et al., Neuro Oncol. 2012 14(4):333-43.

Page 2: Ellingson BM  et al ., Neuro Oncol. 2012 14(4):333-43

Ellingson BM et al., Neuro Oncol. 2012 14(4):333-43. Ellingson BM et al., Neuro Oncol. 2011 13(10):1151-61

Page 3: Ellingson BM  et al ., Neuro Oncol. 2012 14(4):333-43

- Instead of quantifying the absolute difference in ADC, CIMPLE maps examines the rate of change and spatial changes in ADC

-PROLIFERATION MAPPING uses the CIMPLE map equation, but assumes no invasion (simplified version of CIMPLE map…need only two time points).

-Example: If ADC in one region has decreased from 1.6 to 1.0 um2/ms over the course of 1 year and another region has a decrease in ADC from 1.6 to 1.0 um2/ms over the course of the last month, fDMs would say these are equally “hypercellular”. CIMPLE maps (or proliferation maps) would say that these two regions have different rates of change in ADC and therefore different proliferation rates.

ΔADC = ADCnew − ADCbaselinefDMs

ρ =1

t⋅ln

ADCbaselineADCnew

⎝⎜⎞

⎠⎟CIMPLE/Proliferation Maps

Page 4: Ellingson BM  et al ., Neuro Oncol. 2012 14(4):333-43
Page 5: Ellingson BM  et al ., Neuro Oncol. 2012 14(4):333-43
Page 6: Ellingson BM  et al ., Neuro Oncol. 2012 14(4):333-43
Page 7: Ellingson BM  et al ., Neuro Oncol. 2012 14(4):333-43
Page 8: Ellingson BM  et al ., Neuro Oncol. 2012 14(4):333-43
Page 9: Ellingson BM  et al ., Neuro Oncol. 2012 14(4):333-43
Page 10: Ellingson BM  et al ., Neuro Oncol. 2012 14(4):333-43
Page 11: Ellingson BM  et al ., Neuro Oncol. 2012 14(4):333-43
Page 12: Ellingson BM  et al ., Neuro Oncol. 2012 14(4):333-43
Page 13: Ellingson BM  et al ., Neuro Oncol. 2012 14(4):333-43
Page 14: Ellingson BM  et al ., Neuro Oncol. 2012 14(4):333-43
Page 15: Ellingson BM  et al ., Neuro Oncol. 2012 14(4):333-43
Page 16: Ellingson BM  et al ., Neuro Oncol. 2012 14(4):333-43
Page 17: Ellingson BM  et al ., Neuro Oncol. 2012 14(4):333-43
Page 18: Ellingson BM  et al ., Neuro Oncol. 2012 14(4):333-43